Clinical Trials Directory

Trials / Completed

CompletedNCT04718207

Modelling in the Quantitative Analysis of Brain PET Scans in Patients With Alzheimer's Disease

Interest of PFS Modelling in the Quantitative Analysis of Brain PET Scans in Patients With Alzheimer's Disease Acquired on a Numerical System

Status
Completed
Phase
Study type
Observational
Enrollment
25 (actual)
Sponsor
Central Hospital, Nancy, France · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

PET/CT scans with 18F-FDG can be carried out for the detection of neurodegenerative diseases with hypometabolisms characteristic of the pathologies sought. The diagnosis is given by the clinician after a visual analysis of the data. To complete the diagnosis, a semi-quantitative analysis of the images is recommended (European recommendations) in addition to the visual analysis.

Detailed description

PET/CT scans with 18F-FDG can be carried out for the detection of neurodegenerative diseases with hypometabolisms characteristic of the pathologies sought. The diagnosis is given by the clinician after a visual analysis of the data. To complete the diagnosis, a semi-quantitative analysis of the images is recommended (European recommendations) in addition to the visual analysis. PET technology is improving from year to year thanks to the arrival of a new PET technology called digital. In addition, correction methods have been developed to improve PET images and thus improve the detection of different pathologies in PET. The PSF (Point Spread Function) tool enables partial volume effects to be corrected. The PSF consists of correcting the impulse response of the system, and allows a visual improvement of the images. Currently not recommended in brain PET/CT reconstructions, it remains to be evaluated for the quantitative analysis of acquisitions.

Conditions

Interventions

TypeNameDescription
DEVICEBrain positron emission tomopgraphy (PET) - scanPatients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.

Timeline

Start date
2021-02-01
Primary completion
2021-08-01
Completion
2022-02-01
First posted
2021-01-22
Last updated
2022-08-24

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04718207. Inclusion in this directory is not an endorsement.